Literature evidence has shown PSMA-PET to be able to guide stereotactic ablative radiotherapy/stereotactic body radiation therapy (SABR/SBRT) in patients with a lower tumor burden and oligometastatic disease [16,17,18,19]. The gene discussed is FOLH1; the disease is neoplasm.